Nordic Nanovector – Subsequent Offering

Nordic Nanovector (the “Company”) announces that the subscription period for the previously announced subsequent repair offering (the “Offering”) will commence today. The subscription period will end on 12 September 2014 at 16:00 CET. The Offering consists of up to 2,000,000 new shares and the subscription price in the Offering is NOK 25 per share. The shareholders of the Company as of 27 June 2014 (and being registered as such in the Norwegian Central Securities Depository (VPS) on 2 July 2014 (the “Record Date”)),except for shareholders in jurisdictions other than Norway and in which an offer to participate in the share issue is not allowed or would require approval or registration of a prospectus or similar measures, may subscribe for and be allocated shares in the Offering (the “Eligible Shareholders”). The Eligible Shareholders, other than those shareholders who participated in the private placement which was completed in June 2014, will be granted 0.4 non-transferable subscription right (the “Subscription Rights”) for each existing share registered as held by such Eligible Shareholders as of the Record Date. Each Subscription Right provides a preferential right to subscribe to and to be allocated one share at the subscription price in the Offering. Other investors than Eligible Shareholders may not subscribe for or be allocated shares in the Offering. ABG Sundal Collier and DNB Markets are managers for the Offering.

About Nordic Nanovector AS

Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin

Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).

This information was brought to you by Cision http://news.cision.com